Ramipril Capsule
Product Images NDC 51407-709

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Ramipril (NDC 51407-709). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Gsms, Incorporated, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemstructure (Chemstruc)

Chemical structure of Ramipril, illustrating its molecular composition with labeled carbon, hydrogen, oxygen, and nitrogen atoms forming the compound's distinctive rings and chains.*

FDA Label Image

Containerlabel10 (Containerlabel10)

Label for Ramipril Capsules, USP 10 mg oral capsules, supplied in a package of 100 capsules. The label includes instructions to see the package insert for dosing, a warning to keep out of reach of children, storage conditions at 20 to 25°C, and pharmacist dispensing instructions. Marketed by GSMS, Incorporated and manufactured by CorePharma, LLC. The label also features the GSMS logo and a barcode.*

FDA Label Image

Containerlabel2point5 (Containerlabel2point5)

Label for Ramipril Capsules, USP 2.5 mg, oral capsules packaged in a 100 count container. The label lists the active ingredient as Ramipril USP 2.5 mg per capsule, states storage instructions at 20° to 25°C, and includes warnings to keep out of reach of children. The product is marketed by GSMS, Incorporated and manufactured by CorePharma, LLC.*

FDA Label Image

Containerlabel5 (Containerlabel5)

Label for Ramipril Capsules USP 5 mg oral capsules, presented in a package of 100 capsules. The label includes the NDC 51407-708-01, manufacturer CorePharma LLC, and marketing by GSMS Incorporated. The label lists dosage, storage instructions, warnings, and pharmacy dispensing information.*

FDA Label Image

Figure1 (Figure1)

A line graph depicting the proportion of patients over days of follow-up for Ramipril versus placebo. The graph shows two lines: a solid line for Ramipril and a dashed line for placebo, with the placebo line consistently higher. A statistical annotation (P=0.0001) is present, indicating significance.*

FDA Label Image

Figure2 (Figure2)

A forest plot depicting the relative risk in the Ramipril group compared to the placebo group across different patient subgroups. The vertical axis lists subgroups such as cardiovascular disease, diabetes, age, sex, hypertension, and others with corresponding patient numbers. Horizontal confidence intervals illustrate the 95% confidence range for relative risk values, centered around 1.0 as the reference line.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.